Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective
Richard T Maziarz, Usama Gergis, Marie Louise Edwards, Yan Song, Qing Liu, Annika Anderson, James Signorovitch, Rocio Manghani, Ronit Simantov, Heayoung Shin, Smitha Sivaraman · 2023
Read Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective by Richard T Maziarz, Usama Gergis, Marie Louise Edwards, Yan Song, Qing Liu, Annika Anderson, James Signorovitch, Rocio Manghani, Ronit Simantov, Heayoung Shin, Smitha Sivaraman (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10912849.txt.
Description
Richard Maziarz and co-authors tally what stem cell transplants from donors cost the United States health system. The procedure, allo-HCT, can cure blood cancers but demands years of care. Conditioning, hospital stays, and complications stack the bills. Their 2023 paper takes the payer's view: what insurers actually spend across the whole arc. More than eight thousand such transplants run each year in the country.
World counts top twenty-four thousand a year. Volumes have climbed for decades as the method spread. The team frames cost as a planning problem, not just a price tag. Therapies that shorten hospital time or cut complication rates could save large sums. The paper gives payers and hospitals a shared cost map.
Catalog record
| CREATOR | Richard T Maziarz, Usama Gergis, Marie Louise Edwards, Yan Song, Qing Liu, Annika Anderson, James Signorovitch, Rocio Manghani, Ronit Simantov, Heayoung Shin, Smitha Sivaraman |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |